Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The company disclosed approval of Symbravo – AXS-07 – for migraine with broad label and hosted a webcast with Dr. Tepper, a well known migraine key opinion leader, and the subsequent commentaries are “highly positive” and consistent with totality of clinical data from Phase 3 INTERCEPT and MOMENTUM trials, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $132 from $116 at Baird
- Axsome Therapeutics hosts SYMBRAVO FDA approval investor event
- Axsome Therapeutics price target raised to $190 from $180 at H.C. Wainwright
- Axsome Therapeutics announces FDA approval of Symbravo
- Axsome Therapeutics price target raised to $155 from $125 at TD Cowen